Drugs / ALMB-0166
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05524103 | Apr 2022 → Feb 2025 | spinal cord injury | AlaMab Therapeutics (Shanghai) Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2025-09-15 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - ALMB-0166 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF PARKINSON'S DISEASE irasia.com ↗ |
| 2023-11-17 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - ALMB-0166 FOR TREATMENT OF ACUTE ISCHEMIC STROKE OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
| 2022-12-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - ALMB-0166 FOR THE TREATMENT OF OSTEOARTHRITIS OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s ALMB-0166 has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trial for the treatment of osteoarthritis in China. |
| 2020-12-01 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG "ALMB-0166" OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗
The board of directors (the “ Board”) of CSPC Pharmaceutical Group Limited (the “ Company ”, together with its subsidiaries, the “Group”) is pleased to announce that AlaMab Therapeutics (Shanghai) Inc.*ʮ ̡ , a subsidiary of the Company, has obtained approval from the National Medical Products Administration of the People’s Republic of China for conducting clinical trial of the investigational new drug ALMB-0166 for the treatment of acute spinal cord injury in China. |
| 2019-10-21 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG ALMB-0166 WAS GRANTED CLINICAL TRIAL APPROVAL IN AUSTRALIA irasia.com ↗ |
| 2019-10-21 | AlaMab Therapeutics (Shanghai) Inc. | Regulatory Clinical Trial Approval in Australia. alamab.com ↗
This clinical trial approval demonstrates the recognition from the regulatory body of the preclinical trial results and clinical trial feasibility of ALMB-0166 as a first-in-class new drug. |
| 2019-08-15 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SUBMISSION OF CLINICAL TRIAL APPLICATION FOR INVESTIGATIONAL FIRST-IN-CLASS NEW DRUG ALMB-0166 IN AUSTRALIA irasia.com ↗
AlaMab Therapeutics Inc., a subsidiary of the Company, has submitted a clinical trial application to the relevant Ethics Committee in Australia for the first-in-human study for its investigational new drug, anti-connexin 43 (Cx43) humanized monoclonal antibody (ALMB-0166). |
| 2019-08-15 | AlaMab Therapeutics (Shanghai) Inc. | Regulatory Submission of Clinical Trial Application in Australia alamab.com ↗
The Board of Directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that AlaMab Therapeutics Inc., a subsidiary of the Company, has submitted a clinical trial application to the relevant Ethics Committee in Australia for the first-in-human study for its investigational new drug, anti-connexin 43 (Cx43) humanized monoclonal antibody (ALMB-0166). |
| 2018-11-26 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - THE GROUP'S PRODUCT CANDIDATE "ALMB-0166" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA irasia.com ↗ |
| 2018-11-26 | AlaMab Therapeutics (Shanghai) Inc. | Regulatory Orphan-Drug Designation by the U.S. FDA alamab.com ↗ |
All press releases naming this drug 10 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALMB-0166 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05524103 ↗ |